---
title: "Nuvalent, Inc. (NUVL.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/NUVL.US.md"
symbol: "NUVL.US"
name: "Nuvalent, Inc."
industry: "Biotechnology"
datetime: "2026-06-19T09:04:07.276Z"
locales:
  - [en](https://longbridge.com/en/quote/NUVL.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/NUVL.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/NUVL.US.md)
---

# Nuvalent, Inc. (NUVL.US)

## Company Overview

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. Nuvalent, Inc. has a strategic partnership with Guardant Health, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [nuvalent.com](https://nuvalent.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -21.66 | 504 | - | - | - |
| PB | 8.30 | 381 | 9.30 | 6.64 | 5.95 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-06-10T04:00:00.000Z

Total Analysts: **17**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 1 | 6% |
| Hold | 16 | 94% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 123.43 |
| Highest Target | 172.00 |
| Lowest Target | 124.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/NUVL.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/NUVL.US/norm.md)
- [Related News](https://longbridge.com/en/quote/NUVL.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/NUVL.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**